Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: May 28, 2009

Premium

Title: Genetic Inhibition by Double-Stranded RNA

Number: 7,538,095

Filed: Oct. 30, 2002

Lead Inventor: Andrew Fire, Carnegie Institution of Washington

The patent, its abstract states, claims "a process … of introducing an RNA into a living cell to inhibit gene expression of a target gene in that cell. The process may be practiced ex vivo or in vivo.

"The RNA has a region with double-stranded structure," the abstract adds. "Inhibition is sequence-specific in that the nucleotide sequences of the duplex region of the RNA and of a portion of the target gene are identical. The … invention is distinguished from prior art interference in gene expression by antisense or triple-strand methods."


Title: Reduction of Off-Target RNA Interference Toxicity

Number: 20090130751

Filed: May 29, 2008

Lead Inventor: Beverly Davidson, University of Iowa

The invention, the patent application's abstract states, "is directed to RNA interference molecules targeted against a nucleic acid sequence, and methods of using these RNAi molecules to reduce off-target toxicity."


Title: Low-Density Lipoprotein Receptor-Mediated siRNA Delivery

Number: 20090131358

Filed: Nov. 14, 2008

Inventor: Jon Chatterton, Alcon

"The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo," the patent application's abstract states. "The conjugates comprise a ligand that can bind to a low-density lipoprotein receptor or LDLR family member. Therapeutic uses for the conjugates are also provided."


Title: Tripartite RNAi Constructs

Number: 20090131360

Filed: Oct. 2, 2008

Lead Inventor: Tod Woolf, RXi Pharmaceuticals

The invention, the patent application's abstract states, "provides compositions and methods for inhibiting expression of a target gene in a cell. The process comprises introduction of double-stranded tripartite RNAi constructs into the cells and reducing the expression of the corresponding messenger RNA in the cells. The constructs, which may be packaged in or delivered as sequestered RNAi constructs, differ from the canonical siRNA in that they comprise a tripartite structure which follows the general formula of having an RNAi core (either native or abbreviated), one or more terminal moieties attached to the RNAi core, and, optionally, a linker between the RNAi core and the terminal moiety," the abstract states. "Once packaged into sequestration vehicles, the constructs are activated for gene regulation by the application of certain forms of energy."


Title: Inducible siRNA-Expression Cassette and Method of Use

Number:
20090133136

Filed: Jan. 18, 2006 PCT Filed: Jan. 18, 2006

Lead Inventor:
Demin Zhou, Immusol

The patent application, its abstract states, claims "an inducible siRNA-expression polynucleotide and methods for its use. … The expression polynucleotide comprises a bicistronic expression cassette that encodes a repressor and a detectable marker, wherein the repressor controls expression of siRNA expression in the absence of an inducer."

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.